Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101. The retrospective study, conducted by a third party statistician group, analyzed the correlation between response to CF101 and patients’ body mass index (BMI) in the Phase 2/3 Psoriasis interim results as well as the recently completed Phase 2 Rheumatoid Arthritis trial. The data shows a significant increase in the response to CF101 in patients with a BMI of over 25 in both studies. These findings corroborate the efficacy seen with other FDA approved drugs such as Cyclosporine A which was more effective in patients with high BMI. The company believes these findings will enable it to optimize the design of its forthcoming Phase 3 studies.
“These new findings are further evidence of CF101’s high efficacy, while the drug continues to show excellent safety in patients. We believe the data will be very important to the design of our forthcoming Phase 3 trials because these findings help us to achieve the maximum potential of the drug in the treatment of inflammatory conditions,” stated Can-Fite CEO Pnina Fishman.
Can-Fite’s Phase 2/3 Psoriasis trial is ongoing with data expected to be released in the first quarter of 2015. The Psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data. The market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects.
The global Rheumatoid Arthritis drug market is expected to generate revenues of $38.5 billion in 2017, according to Visiongain.
Date: August 6, 2014
Source: Can-Fite BioPharma
